BellaSeno Uses 3D-Printed Resorbable Scaffolds for Breast Regeneration

BellaSeno has developed an experimental breast augmentation and reconstruction technique that replaces permanent implants with 3D-printed, resorbable scaffolds. The method aims to trigger the body's own regenerative capacity to create natural tissue in a precise shape.

The process utilizes scaffolds printed from polycaprolactone (PCL), a material designed to be completely reabsorbed by the human body. During the procedure, surgeons harvest the patient's own fat via liposuction from areas such as the thighs and inject it into the porous PCL structures. Over a period of one to two years, the scaffolds gradually degrade as the seeded fat cells multiply and fill the framework, eventually leaving behind only natural breast tissue.

The Shift from Implants

Traditional breast augmentation and reconstruction have long relied on saline or silicone implants. While effective for volume, these foreign bodies carry long-term risks, including scarring and other medical complications. Autologous fat grafting—the practice of transferring a patient's own fat—has been used as an alternative, but it often lacks the structural integrity required to maintain a specific shape over time. BellaSeno’s approach attempts to bridge this gap by combining the structural precision of 3D printing with the safety of the patient's own biological tissue.

Clinical Results and Impact

Thirty women have already participated in clinical trials using these resorbable scaffolds. MRI scans conducted several years after the surgeries show results that are indistinguishable from normal breast tissue.

This development signals a broader move toward "medical regeneration," a field focused on unlocking the body's ability to heal and rebuild itself. This technique represents a significant advancement in breast surgery, signaling that the industry has entered the era of medical regeneration. For millions of patients, including those undergoing reconstructive surgery following mastectomies, this could eliminate the lifelong risks associated with permanent foreign-body implants.

Future Outlook

BellaSeno CEO Dr. Mohit P. Chhaya noted that the progress is the result of years of collaboration between engineers, scientists, and surgeons. While the initial trials show promise, the industry will be watching for larger-scale clinical data to determine if the results remain consistent across diverse patient populations. If commercialized, the technique could redefine the standard of care for both cosmetic and reconstructive breast surgery by providing a permanent, biological solution rather than a synthetic substitute.